Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $237,093.

  • SAB Biotherapeutics' Amortizatization of Intangibles changed negligibly% to $22,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $85,344, marking a year-over-year decrease of 45.91%. This contributed to the annual value of $237,093 for FY2024, which is 137.09% up from last year.
  • As of FY2024, SAB Biotherapeutics' Amortizatization of Intangibles stood at $237,093, which was up 137.09% from $100,000 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Amortizatization of Intangibles ranged from a high of $237,093 in FY2024 and a low of $100,000 during FY2023.
  • In the last 3 years, SAB Biotherapeutics' Amortizatization of Intangibles had a median value of $122,449 in 2022 and averaged $153,181.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first declined by 25.78% in 2022, then soared by 137.09% in 2024.
  • SAB Biotherapeutics' Amortizatization of Intangibles (Yearly) stood at $165,036 in 2020, then fell by 0.03% to $164,983 in 2021, then decreased by 25.78% to $122,449 in 2022, then declined by 18.33% to $100,000 in 2023, then soared by 137.09% to $237,093 in 2024.